PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
试验观察：基于树突状细胞（DC）的癌症免疫治疗
英文原题：Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
查看英文原题
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
基于树突状细胞（DC）的癌症治疗疫苗在过去几十年中取得了长足发展。然而，由于近期T细胞靶向免疫疗法所引发的免疫肿瘤学范式转变，该领域目前正处于向利基应用转型的状态。DC疫苗通常使用自体（患者来源）DC制备，这些DC在免疫刺激分子存在下暴露于肿瘤相关或肿瘤特异性抗原（TAAs或TSAs）以诱导DC成熟，随后回输给患者。因此，DC疫苗可诱导TAA/TSA特异性CD8+/CD4+T细胞应答。然而，DC疫苗接种在临床中仍显示出次优的抗肿瘤疗效。目前正在进行大量努力以提高DC疫苗的免疫原性和疗效，通常采用联合化疗-免疫治疗方案。在本期Trial Watch中，我们总结了该领域近期的临床前和临床进展，并讨论了基于DC的免疫疗法用于肿瘤适应症的当前趋势和未来前景。
展开英文摘要原文
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades.
However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8 + /CD4 + T cell responses.
Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.
论文信息
- 作者
- Laureano RS、Sprooten J、Vanmeerbeerk I、Borras DM、Govaerts J、Naulaerts S、Berneman ZN、Beuselinck B
- 单位
- Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium.Belgium
- 文献类型
- 非美国政府资助研究
- 期刊
- Oncoimmunology2022
- 原文标识
- PubMed 35800158 · DOI 10.1080/2162402X.2022.2096363
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →